Anti-HIV adaptive immunity: Determinants for viral persistence

Reviews in Medical Virology

Volumn 18, Issue 5, 2008, Pages 293-303

  Yamamoto, Hiroyuki ^a   Matano, Tetsuro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; ANTIVIRAL ACTIVITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL THERAPY; CELLULAR IMMUNITY; COHORT ANALYSIS; CYTOTOXIC T LYMPHOCYTE; DISEASE CONTROL; DNA POLYMORPHISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOREACTIVITY; INFECTION CONTROL; MEMORY T LYMPHOCYTE; NONHUMAN; PERSISTENT INFECTION; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; T CELL DEPLETION; VACCINE PRODUCTION; VIREMIA; VIRUS CELL INTERACTION; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; VIRUS SURVIVAL; VIRUS VIRULENCE;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY; NEUTRALIZATION TESTS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES, CYTOTOXIC; VIRAL LOAD; VIREMIA;

EID: 52649135599     PISSN: 10529276     EISSN: None     Source Type: Journal    
DOI: 10.1002/rmv.577     Document Type: Review

References (115)

1. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996; 272: 872-877.
2. Deng H, Liu R, Ellmeier W, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996; 381: 661-666.
3. + cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 383: 667-673.
4. Endres MJ, Clapham PR, Marsh M, et al. CD4-independent infection by HIV-2 is mediated by fusin/CXCR4. Cell 1996; 87: 745-756.
5. Wolinsky SM, Wike CM, Korber BT, et al. Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. Science 1992; 255: 1134-1136.
6. McNearney T, Hornickova Z, Markham R, et al. Relationship of human immunodeficiency virus type 1 sequence heterogenicity to stage of disease. Proc Natl Acad Sci USA 1992; 89: 10247-10251.
7. Zhu T, Mo H, Wang N, et al. Genotypic and phenotypic characterization of HIV-1 in patients with primary infection. Science 1993; 261: 1179-1181.
8. + T cell depletion and viral replication in SIV infection. Science 1998; 280: 427-431.
9. + T cells in lymphoid tissues during simian immunodeficiency virus infection. J Virol 2000; 77: 9710-9715.
10. Pitcher CJ, Hagen SI, Walker JM, et al. Development and homeostasis of T cell memory in rhesus macaque. J Immunol 2002; 168: 29-43.
11. + T cell subsets in rhesus monkeys, explaining their divergent clinical courses. Proc Natl Acad Sci USA 2004; 101: 12324-12329.
12. + memory T cells in rapidly progressive simian immunodeficiency virus infection. J Exp Med 2004; 200: 1299-1314.
13. + T cells in multiple tissues during acute SIV infection. Nature 2005; 434: 1093-1097.
14. + T cells depletes gut lamina propria CD4+ T cells. Nature 2005; 434: 1148-1152.
15. Picker LJ, Watkins DI. HIV pathogenesis: the first cut is the deepest. Nat Immunol 2005; 6: 430-432.
16. + T cells are massively infected and eliminated by X4-tropic simian-human immunodeficiency viruses in macaques. Proc Natl Acad Sci USA 2005; 102: 8000-8005.
17. Barouch DH, Santra S, Schmitz JE, et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000; 290: 486-492.
18. Amara RR, Villinger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001; 292: 69-74.
19. Matano T, Kano M, Nakamura H, et al. Rapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNA prime/Sendai virus vector boost regimen. J Virol 2001; 75: 11891-11896.
20. Rose NF, Marx PA, Luckay A, et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 2001; 106: 539-549.
21. Shiver JW, Fu TM, Chen L, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency virus immunity. Nature 2002; 415: 331-335.
22. Willey RL, Byrum R, Piatak M, et al. Control of viremia and prevention of simian-human immunodeficiency virus-induced disease in rhesus macaques immunized with recombinant vaccinia viruses plus inactivated simian immunodeficiency virus and human immunodeficiency virus particles. J Virol 2003; 77: 1163-1174.
23. Feinberg MB, Moore JP. AIDS vaccine models: challenging challenge viruses. Nat Med 2002; 8: 207-210.
24. Horton H, Vogel TU, Carter DK, et al. Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial virus replication but does not prevent disease progression following challenge with pathogenic SIVmac239. J Virol 2002; 76: 7187-7202.
25. Casimiro DR, Wang F, Schleif A, et al. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag. J Virol 2005; 79: 15547-15555.
26. Mattapallil JJ, Douek DC, Buckler-White A, et al. Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge. J Exp Med 2006; 203: 1533-1541.
27. + central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 2006; 312: 1530-1533.
28. Wilson NA, Reed J, Napoe GS, et al. Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol 2006; 80: 5875-5885.
29. Matano T, Kobayashi M, Igarashi H, et al. Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. J Exp Med 2004; 199: 1709-1718.
30. Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68: 4650-4655.
31. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994; 68: 6103-6110.
32. Matano T, Shibata R, Siemon C, Connors M, Lane HC, Martin MA. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J Virol 1998; 72: 164-169.
33. + lymphocytes. Science 1999; 283: 857-860.
34. Jin X, Bauer DE, Tittleton SE, et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 1999; 189: 991-998.
35. Goulder PJ, Watkins DI. HIV and SIV CTL escape: implications for vaccine design. Nat Rev Immunol 2004; 4: 630-640.
36. McNeil AC, Shupert WL, Iyasere CA, et al. High-level HIV-1 viremia suppresses antigen-specific CD4(+) T cell proliferation. Proc Natl Acad Sci USA 2001; 98: 13878-13883.
37. + T cells. Nature 2002; 417: 95-98.
38. Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006; 443: 350-354.
39. + T cell survival in HIV infection. J Exp Med 2006; 203: 2281-2292.
40. + T cells leads to reversible immune dysfunction. Nat Med 2006; 12: 1198-1202.
41. Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC. Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med 1995; 332: 228-232.
42. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382: 668-669.
43. Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996; 2: 1240-1243.
44. Carrington M, Nelson GW, Martin MP, et al. HLA and HIV-1: heterozygote advantage and B*35-Cw-04 disadvantage. Science 1999; 283: 1748-1752.
45. Kaslow RA, Carrington M, Apple R, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996; 2: 405-411.
46. Goulder PJ, Bunce M, Krausa P, et al. Novel, cross-restricted, conserved, and immunodominant cytotoxic T lymphocyte epitopes in slow progressors in HIV type 1 infection. AIDS Res Hum Retroviruses 1996; 12: 1691-1698.
47. Migueles SA, Sabbaghian MS, Shupert WL, et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci USA 2000; 97: 2709-2714.
48. Tang J, Tang S, Lobashevsky E, et al. Favorable and unfavorable HLA class 1 alleles and haplotypes in Zambians predominantly infected with clade C human immunodeficiency virus type 1 in Zambia. J Virol 2002; 76: 8276-8284.
49. Kiepiela P, Leslie AJ, Honeyborne I, et al. Dominant influence of HLA-B in mediating the potential coevolution of HIV and HLA. Nature 2004; 432: 769-775.
50. Bailey JR, Williams TM, Siliciano RF, Blankson JN. Maintenance of viral suppression in HIV-1-infected HLA-B*57 elite suppressors despite CTL escape mutations. J Exp Med 2006; 203: 1357-1369.
51. Muhl T, Krawczak M, Ten Haaft P, Hunsmann G, Sauermann U. MHC class I alleles influence set-point viral load and survival time in simian immunodeficiency virus-infected rhesus monkeys. J Immunol 2002; 169: 3438-3446.
52. Mothe BR, Weinfurter J, Wang C, et al. Expression of the major histocompatibility complex class I molecule Mamu-A*01 is associated with control of simian immunodeficiency virus SIVmac239 replication. J Virol 2003; 77: 2736-2740.
53. Yant LJ, Friedrich TC, Johnson RC, et al. The high-frequency major histocompatibility complex class I allele Mamu-B*17 is associated with control of simian immunodeficiency virus SIVmac239 replication. J Virol 2006; 80: 5074-5077.
54. Loffredo JT, Maxwell J, Qi Y, et al. Mamu-B*08-positive macaques control simian immunodeficiency virus replication. J Virol 2007; 81: 8827-8832.
55. Peyerl FW, Barouch DH, Yeh WW, et al. Simian-human immunodeficiency virus escape from cytotoxic T lymphocyte recognition at a structurally constrained epitope. J Virol 2003; 77: 12572-12578.
56. Friedrich TC, Dodds EJ, Yant LJ, et al. Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nat Med 2004; 10: 275-281.
57. Leslie AJ, Pfafferott KJ, Chetty P, et al. HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 2004; 10: 282-289.
58. Kobayashi M, Igarashi H, Takeda A, Kato M, Matano T. Reversion in vivo after inoculation of a molecular proviral DNA clone of simian immunodeficiency virus with a cytotoxic T-lymphocyte escape mutation. J Virol 2005; 79: 11529-11532.
59. Kawada M, Igarashi H, Takeda A, et al. Involvement of multiple epitope-specific cytotoxic T-lymphocyte responses in vaccine-based control of simian immunodeficiency virus replication in rhesus macaques. J Virol 2006; 80: 1949-1958.
60. Goulder PJ, Phillips RE, Colbert RA, et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 1997; 3: 212-217.
61. Barouch DR, Kunstman J, Kuroda MJ, et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 2002; 415: 335-339.
62. Feeney ME, Tang Y, Roosevelt KA, et al. Immune escape precedes breakthrough HIV-1 viremia and broadening of the CTL response in a HLA-B-27-positive long-term non-progressing child. J Virol 2004; 78: 8927-8930.
63. Frahm N, Kiepiela P, Adams S, et al. Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol 2006; 7: 173-178.
64. + T-cell responses are involved in durable control of AIDS virus replication. J Virol 2007; 81: 3465-3476.
65. + T-cell preservation after nonsterile protection by a cytotoxic T-lymphocyte-based vaccine. J Virol 2007; 81: 5202-5211.
66. + T cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J Virol 1997; 71: 3120-3128.
67. + T lymphocytes at suppressing simian immunodeficiency virus replication in a functional in vitro assay. J Virol 2005; 79: 14986-14991.
68. + cells able to suppress CCR5-tropic simian immunodeficiency virus replication by controlled infection of CXCR4-tropic simian-human immunodeficiency virus in vaccinated rhesus macaques. J Virol 2007; 81: 11640-11649.
69. + T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression. J Immunol 2007; 178: 2746-2754.
70. + T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007; 13: 46-53.
71. Burton DR, Desrosiers RC, Doms RW, et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004; 5: 233-236.
72. Kwong PD, Doyle ML, Casper DI, et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002; 420: 678-682.
73. Wei X, Decker JM, Wang S, et al. Antibody neutralization and escape by HIV-1. Nature 2003; 422: 307-312.
74. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 2003; 100: 4144-4149.
75. Johnson WE, Liffson JD, Lang SM, Johnson RP, Desrosiers RC. Importance of B-cell responses for immunological control of variant strains of simian immunodeficiency virus. J Virol 2003; 77: 375-381.
76. Schmitz JE, Kuroda MJ, Santra S, et al. Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus. J Virol 2003; 77: 2165-2173.
77. + lymphocytes cooperate to control acute simian immunodeficiency virus/human immunodeficiency virus chimeric virus infections in rhesus monkeys: modulation by major histocompatibility complex genotype. J Virol 2005; 79: 14887-14898.
78. Mascola JR, Lewis MG, Stiegler G, et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999; 73: 4009-4018.
79. Shibata R, Igarashi T, Haigwood N, et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 1999; 5: 204-210.
80. Mascola JR, Stiegler G, VanCott TC, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000; 6: 207-210.
81. Nishimura Y, Igarashi T, Haigwood N, et al. Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. J Virol 2002; 76: 2123-2130.
82. Moore JP, Burton, DR. HIV-1 neutralizing antibodies: how full is the bottle? Nat Med 1999; 5: 142-144.
83. Putkonen P, Thorstensson P, Ruden U, et al. Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys. Nature 1991; 352: 436-438.
84. Lewis MG, Elkins WR, McCutchan FE, et al. Passively transferred antibodies directed against conserved regions of SIV envelope protect macaques from SIV infection. Vaccine 1993; 11: 1347-1355.
85. Parren PW, Marx PA, Hessel AJ, et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 2001; 75: 8340-8347.
86. Veazey RS, Shattock RJ, Pope M, et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 2003; 9: 343-346.
87. Hessel AJ, Hangartner L, Hunter M, et al. Fc receptor but not complement activation is important in antibody protection against HIV. Nature 2007; 352: 436-438.
88. Nishimura Y, Igarashi T, Haigwood NL, et al. Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. Proc Natl Acad Sci USA 2003; 100: 15131-15136.
89. Haigwood NL, Watson A, Sutton WF, et al. Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile. Immunol Lett 1996; 51: 107-114.
90. Haigwood NL, Montefiori DC, Sutton WF, et al. Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies. J Virol 2004; 78: 5983-5995.
91. Binley JM, Clas B, Gettie A, et al. Passive infusion of immune serum into simian immunodeficiency virus-infected rhesus macaques undergoing a rapid disease course has minimal effect on plasma viremia. Virology 2000; 270: 237-249.
92. Gauduin MC, Parren PWHI, Weir R, et al. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat Med 1997; 3: 1389-1393.
93. Poignard P, Sabbe R, Picchio GR, et al. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity 1999; 10: 431-438.
94. Yamamoto H, Kawada M, Takeda A, Igarashi H, Matano T. Post-infection immunodeficiency virus control by neutralizing antibodies. PLoS ONE 2007; 2: e540.
95. Kwong PD, Wyatt R, Robinson J, et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998; 393: 648-659.
96. Wyatt R, Kwong PD, Desjardins E, et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 1998; 393: 705-711.
97. Chen B, Vogan EM, Gong H, et al. Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 2005; 433: 834-841.
98. Zanetti G., Briggs JA, Grunewald K, Sattentau QJ, Fuller SD. Cryo-electron tomographic structure of an immunodeficiency virus envelope complex in situ. PLoS Pathog 2006; 2: e83.
99. McMichael AJ. HIV vaccines. Annu Rev Immunol 2006; 24: 227-255.
100. Saphire EO, Parrew PW, Pantophlet R, et al. Crystal structure of a neutralizing IgG against HIV-1: a template for vaccine design. Science 2001; 293: 1155-1159.
101. Calarese DA, Scanlan CN, Zwick MB, et al. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 2003; 300: 2065-2071.
102. Zwick MB, Komori HK, Stanfield RL, et al. The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5. J Virol 2004; 78: 3155-3161.
103. Haynes BF, Fleming J, St Clair EW, et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005; 308: 1906-1908.
104. Trkola A, Kuster H, Rusert P, et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005; 11: 615-622.
105. Burton DR, Stanfield RL, Wilson IA. Antibody vs. HIV in a clash of evolutionary titans. Proc Natl Acad Sci USA 2005; 102: 14943-14948.
106. Nimmerjahn F, Ravetch JV. Fcgamma receptors: old friends and new family members. Immunity 2006; 24: 19-28.
107. Woelbing F, Kostka SL, Moelle K, et al. Uptake of Leishmania major by dendritic cells is mediated by Fcgamma receptors and facilitates acquisition of protective immunity. J Exp Med 2006; 203: 177-188.
108. Regnault A, Lankar D, Lacabanne V, et al. Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med 1999; 189: 371-380.
109. + CTL responses in vivo. J Immunol 2002; 168: 2240-2246.
110. Thomas PG, Brown SA, Yue W, So J, Webby RJ, Doherty PC. An unexpected antibody response to an engineered influenza virus modifies CD8+ T cell responses. Proc Natl Acad Sci USA 2006; 103: 2764-2769.
111. Hangartner L, Zinkernagel RM, Hengartner H. Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol 2006; 6: 231-243.
112. + T cells: when, where, and how. Annu Rev Immunol 2006; 24: 519-540.
113. Staprans SI, Barry AP, Silvestri G, et al. Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein. Proc Natl Acad Sci USA 2004; 101: 13026-13031.
114. Frankel SS, Steinman RM, Michael NL, et al. Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells. J Virol 1998; 72: 9788-9794.
115. + T cells. J Exp Med 2005; 201: 2023-2033.